Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034069 (
pulmonary fibrosis
)
7,050
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Excessive release of neutrophil extracellular traps (NETs) has been implicated in several organ fibrosis, including
pulmonary fibrosis
. NETs constitute a phenomenon in which decorated nuclear chromatin with cytosolic proteins is released into the extracellular space.
PAD4
(peptidylarginine deiminase 4) plays an important role in the formation of NETs. However, the role of NETs in the pathogenesis of
pulmonary fibrosis
remains undefined. Here, we identified NETs in the alveolar and interstitial lung space of mice undergoing bleomycin (BLM)-induced lung fibrosis, which was suppressed by a pan-PAD inhibitor, Cl-amidine.
In vitro
, BLM directly induced NETs in blood neutrophils, which was also inhibited by Cl-amidine. Furthermore,
Padi4
gene knockout (PAD4-KO) in mice led to the alleviation of BLM-induced NETs and
pulmonary fibrosis
and to the expression of inflammatory and fibrotic genes.
PAD4
deficiency prevented decreases in alveolar epithelial and pulmonary vascular endothelial cell numbers and increases in ACTA2-positive mesenchymal cells and S100A4-positive fibroblasts in the lung. Hematopoietic cell grafts from
PAD4
-KO mice, not wild-type mice, resolved BLM-induced lung fibrosis and fibrotic gene expression in wild-type and
PAD4
-KO mice, suggesting that expression of
PAD4
in hematopoietic cells may be involved in the development of lung fibrosis. These data suggest that
PAD4
deficiency could ameliorate BLM-induced formation of NETs and lung fibrosis, suggesting that this pathway could serve as a therapeutic target for
pulmonary fibrosis
treatment.
...
PMID:PAD4 Deficiency Improves Bleomycin-induced Neutrophil Extracellular Traps and Fibrosis in Mouse Lung. 3291 35